Redeye has updated its near-term estimates and valuation following the Q1 report. Kontigo Care has transitioned from an R&D-centric organisation into a commercially driven MedTech product company, aiming to scale its MDR-certified eHealth platform across multiple markets and segments. Although tangible results from intensified sales efforts are still pending, momentum is building as the company navigates prolonged sales cycles and ongoing macroeconomic headwinds.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/